Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-α therapy

Journal of Interferon and Cytokine Research

Volumn 19, Issue 3, 1999, Pages 243-251

  Antonelli, Guido ^a   Simeoni, Eleonora ^b   Turriziani, Ombretta ^a,b   Tesoro, Ramon ^b   Redaelli, Alessandro ^a   Roffi, Luigi ^c   Antonelli, Laura ^d   Pistello, Mauro ^a   Dianzani, Ferdinando ^b,e  

^a UNIVERSITY OF PISA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA ACTIN; HEPATITIS C ANTIBODY; MESSENGER RNA; PROTEIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CHRONIC ACTIVE HEPATITIS; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032942966     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099314171     Document Type: Article

References (47)

1. DAVIS, G.L., BALART, L.A., SCHIFF, E.R., LINDSAY, K., Jr., BODENHELMER, H.C., PERILLO, R.P., CAREY, W., JACOBSON, I.M., PAYNE, J., DIENSTAG, J.L., VAN THIEL, D.H., TAMBURRO, C., LEFKOWITCH, J., ALBRECHT, J., MESCHIEVITZ, C., ORTEGO, T.J., GIBAS, A., and THE HEPATITIS INTERVENTIONAL THERAPY GROUP. (1989). Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled study. N. Engl. J. Med. 321, 1501-1506.
2. DI BISCEGLIE, A.M., MARTIN, P., KASSIANIDES, C., LISKER-MELMAN, M., MURRAY, L., WAGGONER, J., GOODMAN, Z., BANKS, S.M., and HOOFNAGLE, J.H. (1989). Recombinant interferon alpha therapy for chronic hepatitis C: a randomized double-blind placebo-controlled trial. N. Engl. J. Med. 321, 1506-1510.
3. LAU, J.Y.N., MIZOKAMI, M., OHNO, T., DIAMOND, D.A., KNIFFEN, J., and DAVIS, G.L. (1993). Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 342, 1208-1209.
4. HOOFNAGLE, J.H., and DI BISCEGLIE, A.M. (1997). The treatment of chronic viral hepatitis. N. Engl. J. Med. 336, 347-356.
5. OKADA, S., AKAHANE, Y., SUZUKI, H., OKAMOTO, H., and MISHIRO, S. (1992). The degree of variability in the amino terminal regions of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16, 619-624.
6. SHINDO, M., DI BISCEGLIE, A.M., and HOOFNAGLE, J.H. (1992). Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 15, 1013-1016.
7. YOSHIOKA, K., KAKUMU, S., WAKITA, T., ITOH, Y., TAKAYANAGI, M., HIGASHI, Y., SHIBATA, M., and MORISHIMA, T. (1992). Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 16, 293-299.
8. HAGIWARA, H., HAYASHI, N., MITA, E., TAKEHARA, J., KASAHARA, A., FUSAMOTO, H., and KAMADA, T. (1993). Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 104, 877-880.
9. LAU, J.Y.N., DAVIS, G.L., KNIFFEN, J., QIAN, K.P., URDEA, M.S., CHAN, C.S., MIZOKAMI, M., NEUWALD, P.D., and WILBER, J.C. (1993). Significance of serum hepatitis C virus RNA levels in chronic hepatitis. Lancet 341, 1501-1504.
10. TSUBOTA, A., CHAYAMA, K., IKEDA, K., JASUJI, A., KOLDA, I., SAITOH, S., HASHIMOTO, M., IWASAKI, S., KOBAYASHI, M., and HIROMITSU, K. (1994). Factors predictive of response to IFN-α therapy in hepatitis C virus infection. Hepatology 19, 1088-1094.
11. VAN THIEL, D.H., FRIEDLANDER, L., FAGIUOLI, S., WRIGHT, H.I., IRISH, W., and GAVALER, J.S. (1994). Response to interferon alpha therapy is influenced by the iron content of the liver. J. Hepatol. 20, 410-415.
12. MARTINOT-PEIGNOUX, M., MARCELLIN, P., POUTEAU, M., CASTELNAU, C., BOYER, N., POLIQUIN, M., DEGOTT, C., DESCOMBES, I., LE BRETON, V., MILOTOVA, V., BENHAMOU, J.P., and ERLINGER, S. (1995). Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 22, 1050-1056.
13. WADA, M., KANG, K.B., NISHIGAMI, T., SHIMOYAMA, T., and THE HANSHIN CHRONIC HEPATITIS C STUDY GROUP. (1997). Importance of pretreatment viral load and monitoring of serum hepatitis C virus RNA in predicting responses to interferon-α2a treatment of chronic hepatitis C. J. Interferon Cytokine Res. 17, 707-712.
14. ANTONELLI, G. (1997). In vivo development of antibody to interferons: an update to 1996. J. Interferon Cytokine Res. 17, S39-S46.
15. REICHARD, O., ANDERSSON, J., SCHVARCZ, R., and WEILAND, O. (1991). Ribavirin treatment for chronic hepatitis C. Lancet 337, 1058-1061.
16. GOETSCHY, J.F., ZELLER, H., CONTENT, J., and HORISBERGER, M.A. (1989). Regulation of interferon-inducible IFI-78K gene, the human equivalent of the murine Mx gene, by interferons, double-stranded RNA, certain cytokines, and viruses. J. Virol. 63, 2616-2622.
17. HORISBERGER, M.A. (1992). Interferon-induced human protein MxA is a GTPase which binds transiently to cellular proteins. J. Virol. 66, 4705-4709.
18. PITOSSI, F., BLANK, A., SCHRÖDER, A., SCHWARZ, A., HÜSSI, P., SCHWEMMLE, M., PAVLOVIC, J., and STAEHELI, P. (1993). A functional GTP-binding motif is necessary for antiviral activity of MX proteins. J. Virol. 67, 6726-6732.
19. PAVLOVIC, J., ZUCHER, T., HALLER, O., and STAEHELI, P. (1990). Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J. Virol. 64, 3370-3375.
20. FRESE, M., KOCHS, G., MEIER-DIETER, U., SIEBLER, J., and HALLER, O. (1995). Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. J. Virol. 69, 3904-3909.
21. TOMONEN, M., LANKINEN, H., VAPALAHTI, O., RONNI, T., JULKUNEN, I., and VAHERI, A. (1995). Effect of interferon-alpha and cell differentiation on Puumala virus infection in human monocyte/macrophages. Virology 206, 8-15.
22. FRESE, M., KOCHS, G., FELDMANN, H., HERTKRON, C., and HALLER, O. (1996). Inhibition of bunya-, phlebo-, and hantaviruses by human MxA protein. J. Virol. 70, 915-923.
23. ZHAO, H., DE, B.P., DAS, T., and BANERJEE, A.K. (1996). Inhibition of human parainfluenza virus-3 replication by interferon and human MxA. Virology 220, 330-338.
24. LANDIS, H., SIMON-JODICKE, A., KLOTI, A., DI PAOLO, C., SCHNORR, J.J., SCHNEIDER-SCHAULIES, S., HEFTI, H.P., and PAVLOVIC, J. (1998). Human MxA protein confers resistance to Semiliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. J. Virol. 72, 1516-1522.
25. ROERS, A., HOCHKEPPEL, H.K., HORISBERGER, M.A., HOVANESSIAN, A., and HALLER, O. (1994). MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J. Infect. Dis. 169, 807-813.
26. SCHMID, P., ITIN, P., COX, D., MCMASTER, G.K., and HORISBERGER, M.A. (1994). The type I interferon system is locally activated in psoriatic lesions. J. Interferon Res. 14, 229-234.
27. YAMADA, T., HORISBERGER, M.A., KAWAGUCHI, N., MOROO, I., and TOYODA, T. (1994). Immunohistochemistry using antibodies to alpha-interferon and its induced protein, MxA, in Alzheimer's and Parkinson's disease brain tissues. Neurosci. Lett. 181, 61-64.
28. FAH, J., PAVLOVIC, J., and BURG, G. (1995). Expression of MxA protein in inflammatory dermatoses. J. Histochem. Cytochem. 43, 47-52.
29. RONNI, T., SARENEVA, T., PIRHONEN, J., and JULKUNEN, I. (1995). Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J. Immunol. 154, 2764-2774.
30. HALMINEN, M., ILONEN, J., JULKUNEN, I., RUUSKANEN, O., SIMELL, O., and MAKELA, M.J. (1997). Expression of MxA protein in blood lymphocytes discriminates between viral and bacterial infections in febrile children. Pediatr. Res. 41, 647-650.
31. LI, Y., and YOUSSOUFIAN, H. (1997). MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J. Clin. Invest. 100, 2873-2880.
32. VON WUSSOW, P., JAKSCHIES, D., HOCHKEPPEL, H.K., FIBICH, C., and DEICHER, H. (1990). The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur. J. Immunol. 20, 2015-2019.&
33. IMAM, H., JANSON, E.T., GOBL, A., ALM, G., and OBERG, K. (1995). Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response. Anticancer Res. 15, 2191-2195.
34. BEZARES, F., KOHAN, S., SACERDOTE DE LUSTIG, E., PARIAS, E., MURRO, H., and HORISBERGER, M.A. (1996). Treatment strategies for early-stage chronic lymphocytic leukemia: can interferon-inducible MxA protein and tumor necrosis factor play a role as predictive markers of response to interferon therapy? J. Interferon Cytokine Res. 16, 501-505.
35. PISTELLO, M., MENZO, S., GIORGI, S., DA PRATO, L., CAMMAROTA, G., CLEMENTI, M., and BENDINELLI, M. (1994). Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues. Mol. Cell. Probes 8, 229-234.
36. WATSON, A., RANCHALIS, J., TRAVIS, B., MCCLURE, J., SUTTON, W., JOHNSON, P.R., HU, S.L., and HAIGWOOD, N.L. (1997). Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J. Virol. 71, 284-290.
37. LINDSAY, K.L. (1997). Therapy of hepatitis C: overview. Hepatology 26, 71S-77S.
38. STANTON, G.J., LANGFORD, M.J., and DIANZANI, F. (1981). virus yield reduction assay for interferon by titration of Sindbis virus hemagglutinin. Methods Enzymol. 78, 351-357.
39. CHOMCZYNSKI, P., and SACCHI, N. (1987). Single step method of RNA isolation by acid guanidium-phenol-chloroform extraction. Ann. Biochem. 162, 156-159.
40. AEBI, M., FAH, J., HURT, N., SAMUEL, C.E., THOMIS, D., BAZZIGHER, L., PAVLOVIC, J., HALLER, O., and STAEHELI, P. (1989). cDNA structures and regulation of two Interferon-induced Mx proteins. Mol. Cell. Biol. 9, 5062-5072.
41. TOWBIN, H., SCHIMTZ, A., JAKSCHIES, D., VON WUSSOW, P., and HORISBERGER, M.A. (1992). A whole blood immunoassay for the interferon-inducible human Mx protein. J. Interferon Res. 12, 67-74.
42. OH, S.K., LUHOWSKYJ, S., WITT, P., RITCH, P., REITSMA, D., TOWBIN, H., HORISBERGER, M., VON WUSSOW, P., and BLUESTEIN, B. (1994). Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: elimination of protease activity of cell lysates in toto. J. Immunol. Methods 176, 79-91.
43. JAKSCHIES, D., HOCHKEPPEL, H.K., HORISBERGER, M.A., DEICHER, H., and VON WUSSOW, P. (1990). Correlation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanoma. J. Invest. Dermatol. 95, 238S-241S.
44. JAKSCHIES, D., ZACHOVAL, R., MULLER, R., MANNS, M., NOLTE, K.U., HOCHKEPPEL, H.K., HORISBERGER, M.A., DEICHER, H., and VON WUSSOW, P. (1994). Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatology 19, 857-865.
45. RUMP, J.A., JAKSCHIES, D., WALKER, U., SCHLESIER, M., VON WUSSOW, P., and PETER, H.H. (1995). Common variable immunodeficiency (CVID) and MxA-protein expression in blood leucocytes. Clin. Exp. Immunol. 101, 89-93.
46. JONSON, K.P. (1997). The historical development of interferon as multiple sclerosis therapies. J. Mol. Med. 75, 89-94.
47. CHIEUX, V., HOBER, D., HARVEY, J., LION, G., LUCIDARME, D., FORZY, G., DUHAMEL, M., COUSIN, J., DUCOULOMBIER, H., and WATTRè, P. (1998). The MxA protein levels in whole blood lysates of patients with various viral infections. J. Virol. Methods 70, 183-191.